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1. ABSTRACT 
 
Objective: Sleep duration is related to melatonin level, and melatonin is known to influence 
the synthesis and secretion of sex hormones.  We examined the association between sleep 
duration and the risk of prostate cancer in Japanese men. 
Methods: In 1994, 22,320 men (aged 40-79 years) completed a self-administered 
questionnaire including items on sleep duration and other health-related lifestyle factors.  
After 7 years of follow-up, we identified 127 incident cases of prostate cancer.  Cox 
proportional hazard regression analysis was used to estimate hazard ratios (HRs) and the 95% 
confidence intervals (CIs) of prostate cancer incidence according to three categories of sleep 
duration (≤6, 7-8, ≥9 hours), treating 7-8 hours as the reference group with adjustment for age 
and other potential confounders. 
Results: The HR for prostate cancer in men who slept 6 hours or less per day was 1.34 (95% 
CI: 0.83-2.17), and that for men who slept 9 hours or more per day was 0.48 (95% CI: 
0.29-0.79).  The continuous P for trend value, calculated by treating sleep duration as a 
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continuous variable, was 0.02. 
Conclusion: We found an inverse association between sleep duration and the risk of prostate 
cancer incidence in Japanese men. 
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2. INTRODUCTION 
 
Sleep duration and health outcomes 
Sleep is important requirement for a healthy life, similarly to other forms of health-related 
behaviors such as refraining from smoking, taking sufficient physical exercise, and having a 
balanced diet.  Many prospective cohort studies have investigated sleep duration and various 
health outcomes such as all-cause mortality, obesity, diabetes mellitus, hypertension, heart 
disease or cancer (Table 1)
1-33
.  Short sleep duration is associated with all-cause mortality, 
incidence or mortality due to cardiovascular disease (CVD), incidence of diabetes mellitus 
and hypertension.  Long sleep duration is also associated with all-cause mortality, CVD 
mortality or incidence, and the incidence of diabetes mellitus. 
 
Melatonin and sex-hormone related cancer 
Melatonin which is secreted mainly from the pineal gland and plays a role in sleep duration, 
influences the synthesis and secretion of sex hormones by promoting the release of 
6 
gonadotropin-releasing hormone
34-38
.  Several studies have examined the association 
between serum or urinary melatonin levels and sex-hormone-related cancers (Table 2)
39-49
.  
Schernhammer et al. reported that higher urinary 6-sulphatoxymelatonin (aMT6s) levels, as 
measured in the first morning urine, were associated with a lower risk of breast cancer
47, 49
.  
Two cross-sectional studies have found that women with endometrial cancer were lower 
melatonin levels
43, 44
, and one study has reported a lower melatonin level in men with prostate 
cancer
41
. 
    In relation to melatonin, there have been several observational studies of sex-hormone 
related cancers such as those of the prostate, breast, endometrium, or ovary, in individuals 
working night shifts, rotating shifts, or with visual impairment (Table 3)
50-59
.  Night or 
rotating shift workers were increased the risk of prostate, breast and endometrial cancer
53, 55, 56, 
58
.  Furthermore, some studies have examined the risk of prostate and breast cancer in 
individuals with visual impairment, who might not have the potential for decreased melatonin 
production by light at night
50-52, 57
. 
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Sleep duration and the risk of sex-hormone related cancers 
Four epidemiological studies have investigated the relationship between sleep duration and 
breast cancer (Table 4)
21, 25, 31, 60
, and the results were not consistent.  Verkasalo et al. and Wu 
et al. reported an inverse association between sleep duration and breast cancer
21, 31
, Pinheiro et 
al. reported no association
25
, whereas McElroy et al. reported an increased the risk of breast 
cancer in long sleepers
60
.  However, there has been no study of sleep duration and the risk of 
prostate cancer, even though prostate cancer, like breast cancer, is also a sex-hormone related 
cancer. 
 
Objective 
We therefore examined the association between sleep duration and the risk of prostate cancer 
in a population of Japanese men, in whom the incidence and mortality of prostate cancer are 
increasing
61, 62
. 
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3. METHODS 
 
Study population 
Details of the Ohsaki National Health Insurance (NHI) Cohort Study have been described 
previously
63, 64
.  Briefly, this prospective cohort study was started in 1994 and included 
26,481 men aged 40 to 79 years living in the 14 municipalities of Miyagi Prefecture, 
northeastern Japan.  The study used a self-administered questionnaire that included items 
about sleep duration, as well as other health-related lifestyle factors.  The response rate for 
the questionnaire was 94.0% (N=24,895).   
To ascertain the date of and reason for withdrawal from the NHI, we started prospective 
collection of NHI withdrawal history files on January 1, 1995.  We excluded 322 participants 
who had withdrawn from the NHI before the baseline questionnaire survey.  Thus, 24,573 
participants ultimately formed the study cohort. 
 
Exposure data 
9 
The questionnaire included items about sleep duration, as well as consumption of alcohol and 
tobacco, personal and family history of disease, job status, education, body weight, height, 
and walking status.  With regard to the sleep duration, participants answered the mean 
integer number of hours of sleep they had taken per day during the last one year.  Because of 
the small number of samples and cases who slept for less than 7 hours and more than 8 hours, 
we categorized sleep duration into 3 groups: ≤6, 7-8, and ≥9 hours per day.   
 
Follow-up 
The end point was the incidence of prostate cancer defined as the topography code C61.9 
according to the International Classification of Disease for Oncology, Second Edition 
(ICD-O-2).  Clinical stage was classified according to the TNM system as localized (T1 to 
T2), advanced (T3 to T4) or metastatic (N+ and/or M+), or unknown.  We have no 
information on clinical stages of prostate cancer approximately half of the cases in Miyagi 
Prefectural Cancer Registry.  Thus, we used the data of 26 localized prostate cancer cases 
and 31 advanced cancer cases when we conducted the analysis for each clinical stage. 
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We ascertained the incidence of cancer using the Miyagi Prefectural Cancer Registry, one 
of the earliest and most accurate population-based cancer registries in Japan
65
.  In this 
registry, the relevant cases were abstracted from medical records of hospitals by a medical 
doctor or trained medical record reviewer, except for cases reported from an institution to the 
registry.  In order to follow-up the participants for mortality and migration, we reviewed the 
NHI withdrawal history files from 1 January 1995 to 31 December 2001.  When a 
participant was withdrawn from the NHI system because of death, emigration, or employment, 
the date of withdrawal and its reason were coded on the NHI withdrawal history files.  
Because we were unable to obtain subsequent information on participants who withdrew from 
the NHI, we discontinued follow-up of participants who withdrew from the NHI system 
because of emigration or employment. 
We excluded the subjects who had a history of cancer (N=1,509) and those who had 
missing responses for sleep duration (N=653).  We also excluded the subjects those who had 
reported sleep duration of less than 4 hours or more than 12 hours (N=91), because of the 
possibility that these subjects might have some disorders associated with sleep duration.  
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After excluding these subjects, 22,320 subjects remained including 127 subjects with prostate 
cancer.  During the study period (1995-2001), there had been performed no mass screening 
program for prostate cancer in this area. 
 
Ethical permissions 
The study protocol was reviewed and approved by the ethics committee of Tohoku University 
School of Medicine.  We considered the return of self-administered questionnaires signed by 
the participants to imply their consent to participate in the study. 
 
Statistical analysis 
We counted person-years of follow-up for each of the subjects from January 1, 1995, until the 
date of diagnosis of prostate cancer, the date of death, the date of withdrawal from the NHI, or 
the end of follow-up (December 31, 2001), whichever occurred first. 
    We used Cox proportional hazard regression analysis to estimate hazard ratios (HRs) and 
the 95% confidence intervals (CIs) of prostate cancer incidence according to three categories 
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of sleep duration (≤6, 7-8, ≥9 hours), treating 7-8 hours as the reference group.  In these 
analyses, we regarded the following data as covariates: age (<45, 45-49, 50-54, 55-59, 60-64, 
65-69, 70-74, and 75+ years old); marital status (married, or unmarried); education (junior 
high school or less, high school, or college/university or higher); job status (employed, or 
unemployed); history of diseases (presence or absence of history of stroke, hypertension, 
myocardial infarction, or diabetes mellitus); family history of cancer (presence, or absence in 
first-degree relatives); body mass index (BMI; <18.5 kg/m
2
, 18.5-24.9 kg/m
2
, or ≥25.0 
kg/m
2
); cigarette smoking (never smoked, smoked in the past, currently smoking 1-19 
cigarettes/day, or currently smoking ≥20 cigarettes/day); alcohol consumption (never drank 
alcohol, drank in the past, or currently drinking); time spent walking (<1 hour per day, or ≥1 
hour per day).  The continuous P for trend was calculated by treating sleep duration as a 
continuous variable, and categorical P for trend was calculated by treating each category of 
sleep duration as a continuous variable.   
We conducted the stratified analysis and the effect modification by age (<70 or ≥70 years 
old), marital status (married, or unmarried), education (junior high school or less, high school, 
13 
or college/university or higher), job status (employed, or unemployed), history of diseases 
(presence or absence of history of stroke, hypertension, myocardial infarction, or diabetes 
mellitus), family history of cancer (presence, or absence in first-degree relatives), BMI (<18.5 
kg/m
2
, 18.5-24.9 kg/m
2
, or ≥25.0 kg/m2), cigarette smoking (never smoked, smoked in the 
past, or currently smoking), alcohol consumption (never drank alcohol, drank in the past, or 
currently drinking), and time spent walking (<1 hour/day, or ≥1 hour/day), respectively.  
Because of the lack of statistical power, we used different category of covariates, when we 
conducted the stratified analysis and the effect modification.  In addition, the numbers of 
prostate cancer cases were different in each stratified analysis, because of the missing 
responses.  Interactions between the risk of prostate cancer and all confounders were tested 
through the addition of cross-product terms to the multivariate model. 
   All statistical analyses were performed using SAS statistical software, version 9.1 (SAS 
Institute Inc, Cary, NC).  All the statistical tests reported were two-sided.  Differences at P 
values of <0.05 were accepted as statistically significant. 
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4. RESULTS 
 
Baseline characteristics  
Table 5 shows the baseline characteristics of the subjects according to sleep duration.  
Subjects who slept 6 hours or less per day (short sleepers) were more likely to have never 
smoked, to have a higher level of education, and less likely to walk more than 1 hour per day 
than those who slept 7 to 8 hours sleepers, or long sleepers.  Subjects who slept 9 hours or 
more per day (long sleepers) were older, less likely to be employed and married, and more 
likely to have a history of diseases. 
 
Sleep duration and the risk of prostate cancer 
The HR of prostate cancer in men who were short sleepers was 1.34 (95% CI: 0.83-2.17), and 
that for long sleepers was 0.48 (95% CI: 0.29-0.79).  The continuous P for trend, calculated 
by treating sleep duration as a continuous variable, was 0.02.  The categorical P for trend, 
calculated by treating each category of sleep duration as a continuous variable, was 0.0007 
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(Table 6).  Furthermore, we conducted analysis that excluded subjects whose event occurred 
within 3 years after the baseline (N=46), but the result did not change substantially as a 
consequence.  The HR for short sleepers and long sleepers was 1.38 (95% CI: 0.77-2.48) and 
0.36 (95% CI: 0.18-0.72), respectively. 
 
Analysis for each clinical stage of prostate cancer 
We also conducted the analysis for each clinical stage of prostate cancer incidence (localized, 
and advanced or metastatic).  In men with localized prostate cancer (N=26), the HR for short 
sleepers was 1.13 (95% CI: 0.38-3.35), that for long sleepers was 0.29 (95% CI: 0.09-0.997), 
and continuous P for trend was 0.11.  In men with advanced or metastatic prostate cancer 
(N=41), that for short sleepers was 1.82 (95% CI: 0.82-4.05), the HR for long sleepers was 
0.79 (95% CI: 0.35-1.77), and continuous P for trend was 0.30 (Table 7). 
 
The stratified analysis and the effect modification 
Table 8 shows the results of the stratified analysis and the effect modification by age and other 
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covariates on the associations between sleep duration and the risk of prostate cancer.   
P for interactions of each covariate were 0.15, 0.97, 0.20, 0.81, 0.13, 0.45, 0.62, 0.14, 0.21 
and 0.85, for age, marital status, education level, job status, history of diseases, family history 
of cancer, BMI, cigarette smoking, alcohol consumption, and time spent walking, respectively.  
No statistically significant interactions were observed between sleep duration and other 
confounding factors for the risk of prostate cancer on a multiplicative scale.  In men aged 
40-70 years, the HR for short sleepers was 1.25 (95% CI: 0.61-2.58), that for long sleepers 
was 0.69 (95% CI: 0.35-1.35), and continuous P for trend was 0.31.  In men aged 70 years or 
older, the HR for short sleepers was 1.36 (95% CI: 0.72-2.60), that for long sleepers was 0.31 
(95% CI: 0.4-0.66), and continuous P for trend was 0.02.  In subjects who had no history of 
diseases, the HR for short sleepers was 1.49 (95 % CI: 0.82-2.70), that for long sleepers was 
0.35 (95% CI: 0.16-0.74), and P for trend was 0.01.  In subjects who had history of diseases, 
the HR for short sleepers was 1.13 (95% CI: 0.50-2.55), and that for long sleepers was 0.63 
(95% CI: 0.31-1.27), and P for trend was 0.45.   
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5. DISCUSSION 
 
Summary 
We found an inverse association between sleep duration and the risk of prostate cancer in 
Japanese men.  To our knowledge, this is the first study to have addressed the relationship 
between sleep duration and the risk of prostate cancer.  This result would not have been 
affected by recall bias because of the prospective nature of the study, confounding factors 
such as lifestyle or socioeconomic status, or by cancer screening attendance by the study 
subjects, as there was no mass prostate-specific antigen (PSA) screening program in the study 
area during the study period. 
 
Previous studies 
Although there has been no previous study of sleep duration and the risk of prostate cancer, 
one case-control study and three prospective cohort studies of sleep duration and its relation 
to breast cancer have been reported
21, 25, 31, 60
.  Among these previous studies, Verkasalo et al. 
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and Wu et al. reported a decreased risk of breast cancer in long sleepers, Pinheiro et al. 
reported no association between sleep duration and breast cancer, whereas McElroy et al. 
reported an increased risk of breast cancer in long sleepers
21, 25, 31, 60
.  We found an inverse 
association between sleep duration and the risk of prostate cancer, in agreement with the 
findings of Verkasalo et al and Wu et al
21, 31
.  However, our result was not consistent with the 
findings reported by McElroy et al. and Pinheiro et al
25, 60
.  McElroy et al. reported that long 
sleepers had increased risk of breast cancer
60
 in their case-control study, and Pinheiro et al
25
. 
reported that there was no association between sleep duration and the risk of breast cancer in 
their prospective cohort study.  There are several possible reasons for these differences.  
First, since McElroy et al. conducted a case-control study, the difference in study design could 
have accounted for the inconsistency of the results
60
.  Second, Pinheiro et al. used a study 
population comprising residential nurses working in the USA
25
.  Although they accounted 
for rotating shift work, which was likely to have affected sleep patterns and the times that 
sleep occurred, might have been an interesting issue to consider, it might not have been 
possible to generalize their results.  Finally, these previous studies were all focused on breast 
19 
cancer, whereas our outcome was prostate cancer. 
 
Interpretation of the results 
Our results demonstrated an inverse association between sleep duration and the risk of 
prostate cancer.  This means that increased sleep duration was associated with a decreased 
the risk of prostate cancer, and decreased sleep duration was associated with an increased risk 
of prostate cancer.   
    However, an effect of prostate cancer screening on the present results could have been 
considered.  Data from Miyagi Prefectural Cancer Registry, the percentage of prostate cancer 
which detected by medical examination was 2.2% in 1993-1997, and 11.9% in 1998-2002
66,67
.  
In addition, percentage of localized prostate cancer according to identified clinical stage, was 
41.3% in 1993-1997, and 53.3% in 1998-2002.  These data suggested that circumstances for 
prostate cancer diagnosis were different from the present day and the time we conducted the 
baseline survey 
66, 67
.  We therefore conducted the analysis for each clinical stage of prostate 
cancer, however, the result did not change substantially as a consequence.  Although we 
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could not reach a definite conclusion because of the small number of cases, the results for 
each clinical stage of prostate cancer would have shown the same tendency.  We also 
conducted the age-stratified analysis to clarify whether men who underwent PSA screening 
might be younger than men who did not.  However, the results were similar between men 
aged 40-70 years and those aged over 70 years.  Moreover, there was no mass PSA screening 
program in the study area during the study period
68
.  For these reason, if PSA screening does 
exert an effect, it would have only a small impact on our results. 
 
Mechanisms 
Melatonin is suggested to be one of the biological factors playing a role in the inverse 
association between sleep duration and sex hormone-related cancers such as prostate cancer 
and breast cancer
36-38, 69
.  A decreased sleep duration results in a shorter duration of 
nocturnal melatonin secretion
70
.  Melatonin may have an inhibitory effect on gonadal 
function, including the synthesis and secretion of sex hormones, by promoting the release of 
gonadotropin-releasing hormone
34, 35
.  In addition, melatonin exerts an antiproliferative 
21 
effect on prostate and breast cancer cell lines
71-78
.  In turn, a decreased melatonin secretion 
might increase the synthesis and secretion of sex hormones, which might promote the growth 
of sex hormone-related cancer cells. 
Furthermore, in terms of melatonin secretion, previous studies of the association between 
shift or night work have suggested an increased risk of prostate cancer in rotating-shift 
workers
55, 79
, and an increased risk of breast cancer among night workers by meta-analysis
80
.  
In addition, some studies have examined the risk of prostate and breast cancer in individuals 
with visual impairment who might not have the potential for decreased melatonin production 
by light at night
21, 50, 52, 57
.  In such subjects, the incidence of prostate cancer tends to be 
low
50, 57
.  Although there is a meta-analysis from 18 case-control studies, which showed that 
prediagnostic serum concentrations of testosterone, free testosterone, dihydrotestosterone, 
androstanediol glucuronide, dehydroepiandrosterone sulfate, androstenedione, estradiol, or 
free estradiol were not associated with the risk of subsequent prostate cancer, 
81
 this results 
showed only low or normal level of endogenous sex hormones from serum concentration.  
There is no evidence regarding the association between extra high level of endogenous sex 
22 
hormones and prostate cancer.  
  Our results are similar to those of previous studies of the association between night 
work and breast cancer, the association between rotating shift work and prostate cancer, or the 
low risk of prostate or breast cancer in visually impaired subjects, suggesting an influence of 
melatonin secretion.   
 
Study strength 
The major strength of the present study was that it was prospective in nature, and recruited 
subjects from the general population.  In addition, the Miyagi Prefectural Cancer Registry is 
one of the earliest and most accurate population-based cancer registries in Japan
65
.  
Therefore, our data pertaining to the incidence of cancer are considered to be sufficiently 
reliable. 
 
Study limitations 
Our study also had several methodological limitations.  First, we used self-reported sleep 
23 
duration to assess the association between sleep duration and the risk of prostate cancer.  
Therefore some misclassification of sleep duration could have arisen when estimating the 
effect of sleep duration and the risk of prostate cancer incidence.  However, this 
misclassification may have been nondifferential and would have tended to result in 
underestimation of the impact of sleep duration.  Second, we had no information about sleep 
quality, the timing of sleep, the use of sleep medication, or the presence of sleeping disorders.  
Such factors would have an influence on sleep duration and thereby might affect the risk of 
prostate cancer.  Finally, we had no information on rotating-shift work or night work.  
However, more than half of the subjects were farmer or self-employed, and approximately 
20% were retired.  Therefore, we considered that the effect of rotating-shift work or night 
work on the present results was small. 
 
Conclusion 
We have found a significant inverse association between sleep duration and the risk of 
prostate cancer incidence in Japanese men.  Further studies to confirm the effect of sleep 
24 
duration on the incidence of prostate cancer are necessary. 
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Table 1. Prospective cohort studies on the association between sleep duration and major chronic diseases or mortality in adult
First author (year) Setting Follow-up period Number of subjects Number of cases or deaths Outcome
Long sleepers Short sleepers
Hammond EC (1964) US 1959-1962 1,064,004 14,681 Mortality All-cause ↑ ↑
Kripke DF (1979) US 1959-1966 823,065 40,369 Mortality All-cause ↑(aged 50-59 subjects) ↑(aged 50-59 subjects)
Breslow L (1980) US 1965-1974 6,928 717 Mortality All-cause ↑ ↑
Wingard DL (1982) US 1965-1974 6,928 371 Mortality All-cause ↑ ↑
Wingard DL (1983) US 1965-1974 4,713 369 Mortality All-cause ↑ ↑
Kaplan GA (1987) US 1965-1982 6,928 1,219 Mortality All-cause ↑(aged 50-59 subjects) ↑(aged 50-59 subjects)
Pollak CP (1990) US 1984-1988 1,855 309 Mortality All-cause ↑ ↑
Rumble R (1992) UK 1985-1990 1,042 352 Mortality All-cause - -
Huppert FA (1995) UK 1984-1991 1,855 687 Mortality All-cause ↑(men only) -
Qureshi AI (1997) US 1982-1992 7,844 413 Mortality All-cause mortality and stroke ↑(all-cause, stroke) -
Gale C (1998) UK 1973-1998 1,299 1,158 Mortality All-cause ↑ -
Kojima M (2000) Japan 1982-1996 5,322 258 Mortality All-cause - ↑(men only)
Mallon L (2000) Sweden 1983-1995 1,870 266 Mortality All-cause, CAD, cancer, and other ↑(all-cause, CAD; men only) -
Kripke DF (2002) US 1982-1988 1,116,936 undescribed Mortality All-cause ↑ ↑(women only)
Ayas NT (2003) US 1986-1996 71,617 934 Incidence CHD ↑ ↑
Ayas NT (2003) US 1986-1996 70,026 1,969 Incidence Diabetes ↑ ↑
Burazeri G (2003) Israel 1985-1998 1,842 403 Mortality All-cause, CVD, non-CVD ↑(men only)
Patel SR (2004) US 1986-2000 82,969 5,409 Mortality All-cause, CVD, cancer, and other ↑(all-cause, CVD, cancer, other)↑(all-cause, CVD, other)
Tamakoshi A (2004) Japan 1988-1999 104,010 11071 Mortality All-cause ↑ ↑(women only)
Amagai Y (2004) Japan 1992-1999 11,325 495 Mortality All-cause, heart disease, stroke, cancer, and other ↑(women only) ↑(women only)
Table continues.
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Table 1. (Continued)
First author (year) Setting Follow-up period Number of subjects Number of cases or deaths Outcome
Long sleepers Short sleepers
Verkasalo PK (2005) Finland 1976-2000 12,222 242 Incidence Breast cancer ↓ -
Mallon L (2005) Sweden 1983-1995 1,082 88 Incidence Diabetes - ↑(men only)
Yaggi HK (2006) US 1987-2004 1,139 90 Incidence Diabetes ↑ ↑
Gangwisch JE (2006) US 1982-1992 4,810 647 Incidence Hypertension - ↑
Pinheiro SP (2006) UK 1986-2002 77,418 4,223 Incidence Breast cancer - -
Lan TY (2007) Taiwan 1993-2003 3,079 1,338 Mortality All-cause, CVD, cancer, respiratory, and other ↑ -
Hublin C (2007) Finland 1982-2003 21,268 3,700 Mortality All-cause mortality ↑ ↑
Cappuccio FP (2007) UK 1997-2003 3,619 740 Incidence Hypertension - ↑(women only)
Ferrie JE (2007) UK 1985-2004 8,354 566 Mortality All-cause, CVD, non-CVD ↑(all-cause, CVD, non-CVD) ↑(all-cause, CVD, non-CVD)
Ferrie JE (2007) UK 1992-2004 7,729 292 Mortality All-cause, CVD, non-CVD ↑(all-cause, CVD, non-CVD) ↑(all-cause, CVD, non-CVD)
Gangwisch JE (2007) US 1982-1992 8,992 430 Incidence Diabetes ↑ ↑
Wu AH (2008) Singapore 1993-2005 33,528 525 Incidence Breast cancer ↓ (postmenopausal women only)-
Meisinger C (2008) Germany 1984-2002 6,896 380 Incidence Nonfatal or fatal MI - ↑(women only）
Chen JC (2008) US 1994-2005 93,715 926 Incidence Ischemic stroke ↑ -
Abbreviations: CAD=coronary artery disease; CHD=coronary heart disease; CVD=cardiovascular disease; MI=myocardial infarction; ↑=significant increased risk; ↓=significant decreased risk; - =no association
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Table 2. Cross-sectional and case-control studies on the association between melatonin and sex-hormone related cancers
First author (year) Setting Study desgin Cancer site Number of controls Number of cases Results and conclusion
Lissoni P (1990) Italy Cross-sectional Breast 46 25 High melatonin levels in breast cancer patients
Skene DJ (1990) England Cross-sectional Breast 160 10 No association
Bartsch C (1992) Germany Cross-sectional Prostate 9 15 Low melatonin levels in prostate cancer patients
Bartsch C (1997) Germany Cross-sectional Breast 34 17 Low melatonin levels in breast cancer patients
Grin W (1998) Austria Cross-sectional Ovary and Cervical 70 68 Decreased melatonin level in cancer patients
Karasek M (2000) Poland Cross-sectional Ovary and Cervical 23 23 Decreased melatonin level in cancer patients
Travis RC (2004) UK Case-control Breast 353 127 No association
Karasek M (2005) Poland Cross-sectional Cervical 14 31 Decreased melatonin level in cancer patients
Schernhammer ES (2005) US Case-control Breast 291 147 Decreased melatonin level in cancer patients
Carlson LE (2007) Canada Cross-sectional Breast 33 33 No association
Schernhammer ES (2008) US Case-control Breast 710 178 Decreased melatonin level in cancer patients
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Table 3. Prospective cohort studies on the association shift work or visual impairment with hormone-related cancers
First author (year) Settings Study period Number of subjects Number of cases Subjects Outcome Results and conclusion
Feychting M (1998) Sweden 1960-1993 14,859 1,845 Visual impairment All cancer Visual impairment people have a lower cancer incidence
Verkasalo PK (1999) Finland 1983-1996 10,935 799 Visual impairment All cancer and breast cancer Breast cancer risk decreased by degree of visual impairment
Kliukiene J (2001) Norway 1961-1997 15,412 1,655 Visual impairment Breast cancer and other site of cancer Visual impairment people have a lower cancer incidence
Schernhammer ES (2001) US 1988-1998 78,562 2,441 Shift work Breast cancer Increased risk of breast cancer among night shift worker
Schernhammer ES (2003) US 1988-1998 78,586 602 Shift work Colorectal cancer Increased risk of colorectal cancer among night shift worker
Kubo T (2006) Japan 1988-1997 14,052 31 Shift work Prostate cancer Increased risk of prostate cancer among rotating shift worker
Schernhammer ES (2006) US 1989-2001 115,022 1,352 Shift work Breast cancer Increased risk of breast cancer among night shift worker
Pukkala E (2006) Finland 1983-2003 17,557 2,072 Visual impairment All cancer, breast cancer, and prostate cancer Visual impairment people have a lower breast and cancer incidence, but higher all cancer incidence
Viswanathan AN (2007) US 1988-2004 53,487 515 Shift work Endometrial cancer Increased risk of endometrial cancer among night shift worker
Schwartzbaum J (2007) US 1971-1989 3,250,787 6,524 Shift work All cancer, breast cancer, and prostate cancer No association
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Table 4. Epidemiological studies on the association between sleep duration and breast cancer incidence
First author (year) Setting Study design Number of subjects Number of cases Results and conclusion
Verkasalo PK (2005) Finland Prospective cohort 12,222 242 ↓(long sleepers)
Pinheiro SP (2006) US Prospective cohort 77,418 4,223 -
McElroy JA (2006) US Case-control 9,436 4,033 ↑(long sleepers)
Wu AH (2008) Singapore Prospective cohort 33,528 525 ↓(long sleepers; postmenopausal women)
Abbreviations: ↑=significant increased risk; ↓=signficant decreased risk
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Table 5. Baseline characteristics of the subjects according to sleep duration
≤6 7-8 ≥9
Number of subjects 2,671 15,127 4,522
Mean age (years), SD
* 57.7 (11.0) 58.0 (10.4) 64.0 (9.3)
Mean Body Mass Index (kg/m
2
), SD
* 23.7 (3.2) 23.4 (2.9) 23.1 (3.4)
Marital status (%)
Married 80.1 82.2 77.0
Unmarried 12.3 9.8 10.1
Education (%)
Junior high school 49.9 56.5 70.7
High school 34.8 31.6 19.0
College/university or higher 10.6 7.7 3.1
Job status (%)
Employed 59.2 61.0 47.8
Unemployed 13.4 12.8 20.7
History of diseases
†
 (%)
Presence 31.3 29.4 38.9
Absence 68.7 70.6 61.1
Family history of cancer (%)
Presence 30.0 29.3 28.4
Absence 70.0 70.7 71.6
Smoking status
Never smoker (%) 19.4 18.2 15.9
Ex-smoker 25.6 23.2 26.3
Current smoker (<20 cigarettes/day) 14.5 16.0 19.9
Current smoker (≥20 cigarettes/day) 32.2 33.9 25.3
Alcohol consumption
Never drinker 15.5 16.3 14.8
Ex-drinker 10.8 9.1 14.6
Current drinker 70.9 71.6 65.2
Time spent walking (%)
Walking 1 hour per day or more 42.6 45.7 43.4
Walking less than 1 hour per day 51.3 47.3 45.3
*
Standard deviation.
†
History of stroke, hypertension, myocardial infarction, or diabetes mellitus.
Sleep duration (hours/day)
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≤6 7-8 ≥9 P for trend* P for trend†
Person-Years 16,716 94,786 27,104
All prostate cancer
Number of cases 21 87 19
Age-adjusted HR (95% CI) 1.34 (0.83-2.15) 1.00 (reference) 0.46 (0.28-0.75) 0.01 0.0003
Multivariate HR1 (95% CI)
‡ 1.34 (0.83-2.17) 1.00 (reference) 0.48 (0.29-0.79) 0.02 0.0007
Multivariate HR2 (95% CI)
§ 1.38 (0.77-2.48) 1.00 (reference) 0.36 (0.18-0.72) 0.01 0.0009
Table 6. Cox proportional hazard ratios (HRs) for prostate cancer incidence by sleep duration in Japanese men
§
Multivariate HR2 was estimated excluding 46 subjects who were diagnosed with prostate cancer within the first 3 years
from baseline and was adjusted for using the same variables as in multivariable HR1.
‡
Multivariate HR1 was adjusted for age (<45, 45-49, 50-54, 55-59, 60-64, 65-69, 70-74, and 75+ years old); marital status
(married, or unmarried); education (junior high school or less, high school, or college/university or higher); job status
(employed, or unemployed); history of diseases (presence or absence history of stroke, hypertension, myocardial infarction,
or diabetes mellitus); family history of cancer (presence, or absence in first-degree relatives); body mass index (<18.5
kg/m
2
, 18.5-24.9 kg/m
2
, or ≥25.0 kg/m2); cigarette smoking  (never smoked, smoked in the past,  currently smoking 1-19
cigarettes/day, or currently smoking ≥20 cigarettes/day）; alcohol consumption (never drank alcohol, drank in the past, or
currently drinking ); time spent walking (<1hour/day, or ≥1 hour/day).
Sleep duration (hours/day)
*
P for trend values were calculated by treating sleep duration as a continuous variable.
†
P for trend values were calculated by treating each categories of sleep duration as a continuous variable.
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≤6 7-8 ≥9 P for trend* P for trend†
Person-Years 16,716 94,786 27,104
Localized prostate cancer
Number of cases 4 19 3
Multivariate HR1 (95% CI)
‡ 1.13 (0.38-3.35) 1.00 (reference) 0.29 (0.09-0.997) 0.11 0.05
Advanced or metastatic prostate cancer
Number of cases 8 25 8
Multivariate HR1 (95% CI)
‡ 1.82 (0.82-4.05) 1.00 (reference) 0.79 (0.35-1.77) 0.30 0.12
‡
Multivariate HR1 was adjusted for age (<45, 45-49, 50-54, 55-59, 60-64, 65-69, 70-74, and 75+ years old); marital status
(married, or unmarried); education (junior high school or less, high school, or college/university or higher); job status
(employed, or unemployed); history of diseases (history of stroke, hypertension, myocardial infarction, or diabetes mellitus);
family history of cancer (presence, or absence in first-degree relatives); Body Mass Index (<18.5 kg/m
2
, 18.5-24.9 kg/m
2
, or ≥
25.0 kg/m
2
); cigarette smoking  (never smoked, smoked in the past,  currently smoking 1-19 cigarettes/day, or currently
smoking ≥20 cigarettes/day）; alcohol consumption (never drank alcohol, drank in the past, or currently drinking ); walking
status (<1hour/day, or ≥1 hour/day).
†
P for trend values were calculated by treating each categories of sleep duration as a continuous variable.
*
P for trend values were calculated by treating sleep duration as a continuous variable.
Table 7. Cox proportional hazard ratios (HRs) for each clinical stage of prostate cancer incidence by sleep duration in
Japanese men
Sleep duration (hours/day)
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Table 8. Cox proportional hazard ratios (HRs) for prostate cancer incidence by sleep duration stratified by each covariates in Japanese men
≤6 7-8 ≥9 P for trend* P for trend†
Age (P for interaction=0.15)
40-70 years
Number of cases 9 44 11
HR (95%CI)
‡ 1.25 (0.61-2.58) 1.00 (reference) 0.69 (0.35-1.35) 0.31 0.17
70 years or older
Number of cases 12 43 8
HR (95%CI)
‡ 1.36 (0.72-2.60) 1.00 (reference) 0.31 (0.4-0.66) 0.02 0.0005
Marital status (P for interaction=0.97)
Married
Number of cases 16 73 15
HR (95%CI)
‡ 1.20 (0.70-2.07) 1.00 (reference) 0.46 (0.26-0.81) 0.06 0.004
Unmarried
Number of cases 3 6 1
HR (95%CI)
‡ 2.22 (0.52-9.48) 1.00 (reference) 0.36 (0.04-3.11) 0.30 0.10
Education (P for interaction=0.20)
Junior high school or less
Number of cases 16 58 12
HR (95%CI) 1.62 (0.93-2.83) 1.00 (reference) 0.38 (0.20-0.71) 0.0008 <.0001
High school
Number of cases 4 19 6
HR (95%CI)
‡ 1.10 (0.37-2.26) 1.00 (reference) 1.19 (0.47-3.01) 0.20 0.86
College/university or higher
Number of cases 1 9 1
HR (95%CI)
‡ 0.43 (0.05-3.61) 1.00 (reference) 0.44 (0.05-3.77) 0.95 0.97
Job status (P for interaction=0.81)
Employed
Number of cases 8 37 8
HR (95%CI)
‡ 1.28 (0.59-2.76) 1.00 (reference) 0.46 (0.21-1.003) 0.12 0.03
Unemployed
Number of cases 5 24 2
HR (95%CI)
‡ 1.11 (0.42-2.95) 1.00 (reference) 0.20 (0.05-0.88) 0.11 0.03
History of diseases ( P for interaction=0.13)
Absence
Number of cases 14 53 8
HR (95%CI)
‡ 1.49 (0.82-2.70) 1.00 (reference) 0.35 (0.16-0.74) 0.01 0.0006
Presence
Number of cases 7 34 11
HR (95%CI)
‡ 1.13 (0.50-2.55) 1.00 (reference) 0.63 (0.31-1.27) 0.45 0.18
Family history of cancer (P for interaction=0.45)
Presence
Number of cases 9 18 6
HR (95%CI)
‡ 2.84 (1.26-6.37) 1.00 (reference) 0.72 (0.28-1.86) 0.08 0.01
Absence
Number of cases 12 69 13
HR (95%CI)
‡ 0.98 (0.53-1.82) 1.00 (reference) 0.42 (0.23-0.76) 0.08 0.01
Body Mass Index (P for interaction=0.62)
Normal or leanness (≤24.9 kg/m2)
Number of cases 15 65 15
HR (95%CI)
‡ 1.27 (0.72-2.23) 1.00 (reference) 0.52 (0.29-0.92) 0.12 0.01
Obese (≥25.0 kg/m2)
Number of cases 6 20 3
HR (95%CI)
‡ 1.95 (0.77-4.92) 1.00 (reference) 0.30 (0.09-1.04) 0.02 0.006
Cigarette smoking (P for interaction=0.14)
Never smoked
Number of cases 2 21 1
HR (95%CI)
‡ 0.64 (0.15-2.79) 1.00 (reference) 0.11 (0.02-0.86) 0.44 0.08
Smoke in the past
Number of cases 10 31 7
HR (95%CI)
‡ 1.47 (0.71-3.02) 1.00 (reference) 0.51 (0.22-1.17) 0.12 0.03
Currently smoking
Number of cases 9 31 10
HR (95%CI)
‡ 1.83 (0.86-3.88) 1.00 (reference) 0.71 (0.34-1.46) 0.11 0.052
Table continues.
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Table 8. (continued)
≤6 7-8 ≥9 P for trend* P for trend†
Alcohol Consumption (P for interaction=0.21)
Never drank
Number of cases 4 19 4
HR (95%CI)
‡ 1.14 (0.38-3.46) 1.00 (reference) 0.39 (0.13-1.18) 0.53 0.10
Drank in the past
Number of cases 2 11 1
HR (95%CI)
‡ 0.90 (0.20-4.17) 1.00 (reference) 0.19 (0.02-1.48) 0.14 0.16
Currently drinking
Number of cases 15 55 12
HR (95%CI)
‡ 1.53 (0.86-2.72) 1.00 (reference) 0.52 (0.27-0.97) 0.04 0.005
Time spent walking (P for interaction=0.85)
1 hour per day or more
Number of cases 11 31 10
HR (95%CI)
‡ 2.11 (1.06-4.22) 1.00 (reference) 0.74 (0.36-1.53) 0.04 0.02
Less than 1 hour per day
Number of cases 8 47 7
HR (95%CI)
‡ 0.91 (0.43-1.94) 1.00 (reference) 0.34 (0.15-0.76) 0.34 0.03
‡
HR was adjusted for age (<45, 45-49, 50-54, 55-59, 60-64, 65-69, 70-74, and 75+ years old); marital status (married, or unmarried); education
(junior high school or less, high school, or college/university or higher); job status (employed, or unemployed); history of diseases (presence or
absence history of stroke, hypertension, myocardial infarction, or diabetes mellitus); family history of cancer (presence, or absence in first-
degree relatives); body mass index (<18.5 kg/m
2
, 18.5-24.9 kg/m
2
, or ≥25.0 kg/m2); cigarette smoking  (never smoked, smoked in the past,
currently smoking 1-19 cigarettes/day, or currently smoking ≥20 cigarettes/day）; alcohol consumption (never drank alcohol, drank in the past, or
currently drinking ); time spent walking (<1hour/day, or ≥1 hour/day). Each covariates using stratified analysis, did not include each model.
*
P for trend values were calculated by treating sleep duration as continuous variables.
†
P for trend values were calculated by treating each categories of sleep duration as continuous variables.
Sleep duration (hours/day)
 
